MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether MEDI4736 or combination therapy with
MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral
immunologic environment in subjects undergoing resectional surgery for Malignant Pleural
Mesothelioma MPM.